---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022919"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:59:12.857543+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing

## Summary
- Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).
- R&D expenses rose to $37.0M (vs $24.3M) due to PC14586 clinical costs; G&A $18.9M (vs $15.5M).
- Enrollment continues in Phase 1/2 PYNNACLE trial of PC14586 for p53 Y220C advanced solid tumors.
- Phase 1b combo trial with Merck's KEYTRUDA on track to initiate in Q4 2022.
- Appointed Dr. Carol Gallagher to Board; brings 30 years of biotech leadership.

## SEC filing metadata
- accession: 0000950170-22-022919
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/0000950170-22-022919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/pmvp-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022919
- JSON: https://secwatch.observer/filing/0000950170-22-022919.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022919.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/0000950170-22-022919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.